PSA Failure Predicts Death in Men With No, Minimal Comorbidity

This article originally appeared here.
Share this content:
PSA Failure Predicts Death in Men With No, Minimal Comorbidity
PSA Failure Predicts Death in Men With No, Minimal Comorbidity

THURSDAY, Sept. 8, 2016 (HealthDay News) -- Prostate-specific antigen (PSA) failure is associated with increased risk of all-cause mortality for men with intermediate- or high-risk prostate cancer with no or minimal comorbidity, according to a study published online Sept. 6 in the Journal of Clinical Oncology.

Nicholas J. Giacalone, M.D., from Brigham and Women's Hospital in Boston, and colleagues examined whether PSA failure is associated with the risk of all-cause mortality stratified by comorbidity score. Two hundred six men with localized intermediate- and high-risk prostate cancer were randomized to receive radiation therapy or radiation therapy and six months of androgen deprivation therapy.

After a median follow-up of 16.62 years, the researchers found that 76 percent of the men died, and 19 percent of those men died as a result of prostate cancer. Among men with no or minimal comorbidity, PSA failure was associated with an increased risk of all-cause mortality (adjusted hazard ratio, 1.59; 95 percent confidence interval, 1.03 to 2.46; P = 0.04); this was not the case for men with moderate or severe comorbidity (adjusted hazard ratio, 1.75; 95 percent confidence interval, 0.76 to 3.99; P = 0.19).

"Recommending treatment on the basis of reduced PSA failure observed from early results of randomized controlled trials is unlikely to prolong survival in men with moderate-to-severe comorbidity but may prolong survival in men with no or minimal comorbidity, providing evidence to support discussing the early results with these men," the authors write.

One author disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »